Teratology study of two isoglutamine derivatives.
The embryotoxicity and teratogenicity of N-phthalyl isoglutamine (2), a metabolite of thalidomide, and of "K-2004-1c", 2-(bicyclo[2.2.1]heptane-2-endo-3-endo-dicarboximido)-glutaric acid 1-amide (4), the main metabolite of the test compound "K-2004" (proposed generic name: biglumide), a nonteratogenic congener of thalidomide, have been investigated in mice and rats. Whereas 2 proved to be highly teratogenic and embryotoxic, 4 showed none of these activities in the dose range from 50 to 400 mg/kg.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000633:toxicity*; D001952:Bridged-Ring Compounds / Q000633:toxicity*; D055598:Chemical Phenomena; D002621:Chemistry; D004305:Dose-Response Relationship, Drug; D005260:Female; D005298:Fertility / Q000187:drug effects; D005327:Fetal Resorption / Q000139:chemically induced; D017880:Limb Deformities, Congenital; D051379:Mice; D008813:Mice, Inbred ICR; D010797:Phthalimides / Q000633:toxicity; D011247:Pregnancy; D012272:Ribs / Q000002:abnormalities; D013131:Spine / Q000002:abnormalities; D013329:Structure-Activity Relationship; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000633:toxicity
D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D010797:Phthalimides; D013792:Thalidomide; C011611:K 2004-1c; C006161:taglutimide